On November 9, 2026 the FDA required every GLP-1 medicine, including semaglutide (Ozempic, Wegovy, Rybelsus), to carry a warning about NAION, a rare optic-nerve condition. How rare it is, where the concern came from, how strong the evidence is, and which symptoms need a same-day call.
In the trials, most people who stopped semaglutide (Ozempic, Wegovy) regained much of the weight within a year, and gains in blood pressure and blood sugar faded too. The numbers from STEP 1, STEP 4 and tirzepatide’s SURMOUNT-4, and what the evidence says may help.
Most people on semaglutide lose meaningful weight, but not everyone does. How many respond in the trials, why people with type 2 diabetes tend to lose less, what a new gene study found, and what the evidence says about switching or stopping.
Only two randomized trials have compared semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) directly. Tirzepatide led to more weight loss in both. Here are the numbers, the side effects, the different heart-outcome evidence for each, and the caveats.
Stomach and gut problems topped the side-effect list in the main obesity trials of all four drugs. What STEP 1, SURMOUNT-1, TRIUMPH-1 and ATTAIN-1 reported, why the numbers don't line up neatly, and the warnings the class shares.
Body scans from semaglutide and tirzepatide trials show that part of the weight lost is lean mass. Here is how much, why lean mass is not the same as muscle, what a 2026 trial found when people lifted weights, and what is still unknown.
Orforglipron (Foundayo) is a once-daily GLP-1 pill the FDA approved for weight loss in April 2026. What it is, why it isn’t a peptide, what the ATTAIN and ACHIEVE trials found, how it compares with the injections, and its side effects and warnings.
The Wegovy pill (oral semaglutide) and Foundayo (orforglipron) are the two FDA-approved GLP-1 pills for weight loss. How they differ as drugs, how each is taken, what OASIS 4 and ATTAIN-1 found, side effects, and why there is no head-to-head answer yet.
Retatrutide is not approved anywhere yet. Eli Lilly says it plans to submit it to the FDA in the first quarter of 2027. How long FDA review usually takes, what the application will rest on, and why nothing sold as retatrutide today is the real thing.
Retatrutide's first large phase 3 results were published on September 29, 2026. They confirm large average weight loss seen in phase 2, in far more people over a longer time, and add results for knee osteoarthritis and sleep apnea.
CagriSema pairs cagrilintide, a long-acting amylin analogue, with semaglutide in one weekly shot. It cut weight about 20% in its main trial, trailed tirzepatide head to head, and is awaiting an FDA decision. It is not approved.
A GLP-1 medicine turns down your appetite. What you eat with that smaller appetite decides how much of the weight you lose is fat and how much is muscle. Lived experience and the published research on cutting carbs, ketones, electrolytes, kidney stones, muscle, fasting, real food and sleep, including where the evidence is thin.
HHS says it will not act against licensed 503A compounders using six peptides while FDA writes its bulks-list rules. That is not FDA approval, and FDA staff found little or no human data for any of the six.
Ipamorelin is not an approved drug anywhere in the US, the FDA has flagged it as a compounding safety risk, and it was left out of the 2026 HHS peptide policy. What it is, the only two human studies, the side-effect and safety concerns, and why it is banned in sport.
No. BPC-157 is not approved by the FDA for any use, the FDA has flagged it as a compounding safety risk, and its healing evidence comes almost entirely from animal studies.
Some peptides are FDA-approved prescription drugs; most sold online are not. What the FDA has actually said, how pharmacy compounding fits in, and why peptides are not steroids.
Some approved peptide drugs carry cancer warnings, some research peptides raise concerns from lab work, and a few case reports make headlines. What each kind of evidence can and can’t show.
You can’t see purity in a vial, but you can check whether the testing lab really issued the certificate you were shown. Here is how, and what our own checks turned up.
Dozens of online shops sell research peptides, and many look like different companies selling the same products. We compared 15 shops' menus, prices and 98 of their lab reports. The pattern fits a market where many brands buy finished vials from a few manufacturers and sell them under their own labels. So the question to ask isn't "which brand?" but "was the lot I'm buying tested, and does the lab confirm it?"
A roundup of popular tissue repair peptides and what has been tested in people: BPC-157's tiny human record, thymosin beta-4 eye and ulcer trials, GHK-Cu skin studies, TP-508 and LL-37 wound trials, plus FDA and WADA status.
MOTS-c and humanin are made by mitochondria; elamipretide (SS-31) is a drug aimed at them. Mouse data and blood-level studies back the first two; only elamipretide has human trials and a narrow FDA approval.
TB-500 and thymosin beta-4 are often used as if they were the same thing. They are not, and most of the human research involves the full protein, not the fragment sold as TB-500.
Melanotan I and Melanotan II were developed in the same lab to darken skin, but only Melanotan I (afamelanotide) became an approved medicine, for a rare light-sensitivity disease. Melanotan II has only tiny early studies and documented safety concerns.
Repatha, Praluent, Leqvio and the new pill enlicitide all lower LDL cholesterol by targeting the same protein, PCSK9. They are very different kinds of molecules, and only some have been shown to prevent heart attacks and strokes.
We check sellers’ lab reports with the testing labs themselves.
So far 89 of the 105 lab reports we looked up matched the testing lab’s own record, and 12 did not.
A free account shows which sellers, report by report, plus daily prices, deals, Ask PepsRadar and alerts. If you want it, the PepsRadar Weekly brings new research and FDA news once a week. No dosing advice.